DavidLPorterMD

PubMed

• 20 citations
  The Promise of Chimeric Antigen Receptor T-Cell Therapy.
  Noelle V. Frey, David L. Porter
  Oncology. 2016-10-15
• 152 citations
  Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia
  Noelle V. Frey, David L. Porter
  Hematology. American Society of Hematology. Education Program. 2016-12-02
• 234 citations
  Prospective Trial of Chemotherapy and Donor Leukocyte Infusions for Relapse of Advanced Myeloid Malignancies After Allogeneic Stem-Cell Transplantation
  John E. Levine, Thomas Braun, Samuel L. Penza, Patrick Beatty, Kenneth Cornetta
  Journal of Clinical Oncology. 2002-01-15

Journal Articles

• Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium Difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients  
  Edward A Stadtmauer, James K Mangan, Elizabeth O Hexner, David L Porter, Daria V Babushok, Jacqueline Smith, Craig W Freyer, Mindy Schuster, Noelle V Frey, Selina M Lu..., Clinical Infectious Diseases
• Disruption of TET2 Promotes the Therapeutic Efficacy of CD19-Targeted T Cells  
  Shannon A Carty, Carl H June, David L Porter, Bruce L Levine, Rahul M Kohli, Nature
• Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin Lymphoma  
  Stephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood

Abstracts/Posters

• Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecl...
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018